And in 2025, Wegovy also received FDA accelerated approval for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, underscoring that these medications can impact disease processes well beyond body weight alone
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P (2014) Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver
The searches were carried out using the following terms in English as descriptors: Obesity Management, GLP 1 Analogs , Incretins , Diabetes Mellitus being the first combined with the other two, using the Boolean operator And
The wellness market sells BPC-157 as a fix